Incyte (Nasdaq:INCY) announces it has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding disorder, to Incyte’s hematology portfolio. As previously disclosed, under the terms of the parties’ stock purchase agreement, Incyte has acquired all outstanding shares of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones.
Read the full article: Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Its Hematology Portfolio //
Source: https://www.businesswire.com/news/home/20260705825179/en/Incyte-Completes-Acquisition-of-Vega-Therapeutics-a-Wholly-Owned-Subsidiary-of-Star-Therapeutics-Expanding-its-Hematology-Portfolio